Drug and Therapeutics Bulletin 1998;36:77-79; doi:10.1136/dtb.1998.361077
Copyright © 1998 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Update on drugs for herpes zoster and genital herpes

We reviewed the use of aciclovir (Zovirax - Glaxo Wellcome) 6 years ago.1 Since then, two more oral antiherpetic drugs have been licensed - famciclovir (Famvir - SmithKline Beecham) and valaciclovir (Valtrex - Glaxo Wellcome). Here we discuss their efficacy and safety, and review their place in the management of patients with herpes zoster (shingles) and genital herpes, comparing them with aciclovir.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1998 BMJ Publishing Group Ltd.